Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Poll|July 24, 2019
Mini Quiz: Diabetes Distress and Anxiety
Author(s)Awais Aftab, MD
What do we know about psychiatric symptoms that may present in patients who also have diabetes? Take the quiz and learn more.
Advertisement
Which of the following statements is INCORRECT about comorbid anxiety and diabetes mellitus?
Advertisement
Related to this article
Don't miss out on these CME articles! Test your knowledge here.
Cardiologist Mary Branch, MD, reveals how depression, meds, and food insecurity shape heart risk—and why cardiology-psychiatry teamwork matters.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5